Artrya Limited

AYA

AU0000182412

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 11:37:09 2024-06-20 pm EDT			5-day change	1st Jan Change
0.215 ^AUD	-6.52%		-10.42%	-10.42%

Jun. 11	Artrya Signs Five-Year Agreement with Cone Health in US; Shares Decline 4%	MT
Jun. 07	Artrya Submits Second Q-Submission to Finalize FDA Application	MT

Artrya Limited Appoints John Barrington AM as Director

November 25, 2021 at 11:06 pm EST

Artrya Limited announced the appointment of John Barrington AM as Director. Date of appointment is January 24, 2018.

Latest news about Artrya Limited

Artrya Signs Five-Year Agreement with Cone Health in US; Shares Decline 4%	Jun. 10	MT
Artrya Submits Second Q-Submission to Finalize FDA Application	Jun. 06	MT
Artrya Signs Commercial Agreement for Heart Disease Diagnostic Technology; Shares Up 8%	Apr. 01	MT
Artrya Gears Up for US Launch After Tanner Health System Partnership	Mar. 12	MT
Artrya Limited Reports Earnings Results for the Six Months Ended December 31, 2023	Feb. 28	CI
12,000,000 Options of Artrya Limited are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	Nov. 25	CI
15,610,470 Ordinary Shares of Artrya Limited are subject to a Lock-Up Agreement Ending on 26-NOV-2023.	Nov. 25	CI
Artrya Enters US Market Via Strategic Commercial Partnership	Nov. 20	MT
Artrya Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Artrya Completes Q-Submission Meeting with US FDA for Salix Product	23-06-12	MT
Worries of Rate Hike Drag on Financial Markets Send Australian Shares into Losses	23-05-03	MT
Artrya Completes Key Step for US Regulatory Approval of Coronary Artery Software	23-05-03	MT
John Barrington AM to Step Down from the Board and Resign as Managing Director of Artrya Limited	23-03-26	CI
Artrya Limited Announces CEO Changes	23-03-26	CI
Artrya Limited Announces Board Changes	23-02-21	CI
Artrya Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-21	CI
Artrya Obtains UK Regulatory Approval for Salix Coronary Anatomy Product	22-11-07	MT
Artrya Limited Gains UK Regulatory Approval for its Salix Coronary Anatomy Product	22-11-06	CI
Artrya Secures EU Approval for Coronary Analysis Product	22-10-28	MT
Artrya Limited Receives Regulatory Approval for Its Salix Coronary Anatomy Product in Europe	22-10-26	CI
Artrya Limited Announces Executive Changes	22-10-06	CI
Artrya Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Artrya Limited Appoints Jacque Sokolov as Non-Executive Director	22-07-31	CI
Artrya Appoints Medical Chief; Shares Up 5%	22-06-19	MT
Artrya Limited Appoints Jacob Agris as Its New Chief Medical Officer	22-06-19	CI

Artrya Limited is a medical technology company focused on commercializing its artificial intelligence (AI) platform. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. It is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The company has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.

Sector

Healthcare Facilities & Services

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
ARTRYA LIMITED	-10.42%	12.05M
SONIC HEALTHCARE LIMITED	-15.37%	8.55B
RADNET, INC.	+64.74%	4.23B
DR. LAL PATHLABS LIMITED	+3.36%	2.68B
SYNLAB AG	-2.63%	2.61B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-54.53%	1.82B
NEOGENOMICS, INC.	-19.59%	1.66B
FLEURY S.A.	-21.51%	1.42B
METROPOLIS HEALTHCARE LIMITED	+15.98%	1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-48.13%	1.05B